MOG and neuromyelitis optica: Furthermore, we specify how dissemination in time (DIT) was met (presence of CSF-specific oligoclonal bands or new T2/gadolinium-enhancing lesions) and how key mimics (e.g., myelin oligodendrocyte glycoprotein antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), ischemic/hereditary neuropathies) were excluded via antibody testing and clinical/laboratory findings.